Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to monitor the performance of a large metal-on-metal bearing from the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip resurfacing surgery or a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.
| Condition | Intervention | Phase |
|---|---|---|
|
Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis Collagen Disorders Avascular Necrosis Nonunion of Femoral Fractures Congenital Hip Dysplasia Slipped Capital Femoral Epiphysis |
Device: DePuy ASR™ Hip System Device: DePuy ASR™ XL Head / ASR™ Acetabular Cup System |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of a Large Metal-on-Metal (MoM) Bearing Comprising a DePuy ASR™ Cup in Conjunction With Either a DePuy ASR™ Hip Resurfacing Femoral Component or a DePuy ASR™ XL Head in Subjects With Indications Suitable for Either a Primary Resurfacing Arthroplasty or Primary Total Hip Arthroplasty |
- Kaplan-Meier survivorship calculated at the five-year time-point [ Time Frame: 5yrs ] [ Designated as safety issue: Yes ]
- Annual Kaplan-Meier survivorship calculations [ Time Frame: Annually ] [ Designated as safety issue: Yes ]
- Harris Hip Score [ Time Frame: 3mths, 1yr, 2yrs, 5yrs, 10yrs, and 15yrs post-surgery ] [ Designated as safety issue: No ]
- Radiographic analysis [ Time Frame: 3mths, 1yr, 2yrs, 5yrs, 10yrs, and 15yrs post-surgery ] [ Designated as safety issue: No ]
- Oxford Hip Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
- UCLA Activity Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
- Hip Outcome Score [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
- EuroQol EQ-5D [ Time Frame: 3mths, 6mths and annually post-surgery ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 624 |
| Study Start Date: | September 2006 |
| Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Resurfacing system
|
Device: DePuy ASR™ Hip System
Resurfacing system
|
|
Active Comparator: 2
Large Metal-on-Metal Total Hip Replacement
|
Device: DePuy ASR™ XL Head / ASR™ Acetabular Cup System
Large Metal-on-Metal Total Hip Replacement
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
General Inclusion Criteria:
i) Male or female subjects, aged between 18 and 65 years inclusive.
ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.
iii) Subjects, who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Inclusion Criteria for DePuy ASR™ Resurfacing system:
i) Subjects with primary osteoarthritis indicated for standard MoM hip resurfacing arthroplasty with cementless fixation in the acetabulum.
Inclusion Criteria for ASR™ XL Head system:
i) Subjects whose bone morphology and bone quality mean that standard MoM hip resurfacing arthroplasty is not indicated, but for whom cementless fixation in the acetabulum and receipt of a large MoM bearing are still possible.
General Exclusion Criteria:
i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
ii) Subjects with compromised renal function defined as those whose measured values lie outside the normal range for a particular investigational site.
iii) Subjects with proven metal sensitivity.
iv) Subjects with infectious, highly communicable diseases, which may limit follow-up i.e. Active tuberculosis, hepatitis, immuno-compromised conditions, etc.
v) Women who are pregnant or who intend to become pregnant within 2 years of surgery.
vi) Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
vii) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).
viii) Subjects who are currently, or have been in the last 12 months, participating in a clinical study which involves exposure to ionising radiation.
ix) Subjects who are currently involved in any injury litigation claims.
x) Subjects who are undergoing corticosteroid treatment.
xi) Subjects with active or recent joint sepsis.
Additional Exclusion Criteria for DePuy ASR™:
i) Subjects with proven significant osteoporosis and poor bone quality.
ii) Subjects with marked atrophy or deformity in the upper femur, skeletal immaturity, or where loss of musculature or neuromuscular disease would render the procedure unjustifiable.
iii) Subjects whose anatomical CCD angle is below 120°.
iv) Subjects who have undergone irradiation of the affected hip.
Contacts and Locations| Austria | |
| University Clinic for Orthopaedics and Orthopaedic Surgery - LKH | |
| Graz, Austria | |
| Czech Republic | |
| Znojmo Hospital | |
| Znojmo, Czech Republic | |
| Finland | |
| Coxa, Hospital for Joint Replacement | |
| Tampere, Finland | |
| Germany | |
| Klinikum der Universität zu | |
| Köln, Germany | |
| Norway | |
| Elverum Hospital | |
| Elverum, Norway | |
| Portugal | |
| Hospital Curry Cabral | |
| Lisboa, Curry Cabral, Portugal | |
| Switzerland | |
| Kant. Spital Sursee-Wolhusen | |
| Wolhusen, Switzerland | |
| United Kingdom | |
| Royal Berkshire Hospital, UK | |
| Reading, Berkshire, United Kingdom | |
More Information
No publications provided
| Responsible Party: | Jack Mantel, Senior Clinical Research Associate, DePuy International Ltd |
| ClinicalTrials.gov Identifier: | NCT00872547 History of Changes |
| Other Study ID Numbers: | CT05/18 |
| Study First Received: | March 30, 2009 |
| Last Updated: | September 1, 2011 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Keywords provided by DePuy International:
|
Hip Resurfacing Metal-on-Metal |
Large Heads XL Head ASR - osteoarthritis (primary) |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Collagen Diseases Femoral Fractures Hip Dislocation, Congenital Necrosis Osteonecrosis Osteoarthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Fractures, Bone Wounds and Injuries Leg Injuries Musculoskeletal Abnormalities Congenital Abnormalities Pathologic Processes Bone Diseases |
ClinicalTrials.gov processed this record on June 17, 2013